Dr. Joshua M. Bauml on Pembrolizumab Versus Chemo in Head and Neck Cancers

Joshua M. Bauml, MD
Published: Monday, Aug 15, 2016


Joshua M. Bauml, MD, assistant professor of Medicine, Hospital of the University of Pennsylvania and the Veteran's Administration Medical Center, discusses the differences between pembrolizumab (Keytruda) and cytotoxic chemotherapies.

There are currently phase III studies evaluating pembrolizumab in head and neck cancer both in combination with in comparison to cytotoxic chemotherapies. The goal of these trials is to move pembrolizumab into an earlier line, said Bauml.

While pembrolizumab has significantly less toxicities than cytotoxic chemotherapies, the key difference between the two therapies is that pembrolizumab produces much more durable responses, said Bauml.   
 

Joshua M. Bauml, MD, assistant professor of Medicine, Hospital of the University of Pennsylvania and the Veteran's Administration Medical Center, discusses the differences between pembrolizumab (Keytruda) and cytotoxic chemotherapies.

There are currently phase III studies evaluating pembrolizumab in head and neck cancer both in combination with in comparison to cytotoxic chemotherapies. The goal of these trials is to move pembrolizumab into an earlier line, said Bauml.

While pembrolizumab has significantly less toxicities than cytotoxic chemotherapies, the key difference between the two therapies is that pembrolizumab produces much more durable responses, said Bauml.   
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Evolving Applications of Immuno-Oncology Strategies: New Approaches, New Combinations, and New Ways to Care for Lung, Head and Neck, and Bladder CancersAug 31, 20182.0
Publication Bottom Border
Border Publication
x